Serum vascular endothelial growth factor: A prognostic factor in cervical cancer

34Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Purpose To study pre-treatment serum VEGF of patients with invasive cervical cancer and its possible role as prognostic indicator. Methods VEGF was measured using ELISA in the largest patient group (n = 167) to date. Reults Serum VEGF was signiWcantly higher in advanced tumor stage (P = 0.01), large tumor size (tumors larger than 2 cm) (P = 0.03), and the presence of vascular space invasion (P = 0.05). Serum VEGF was associated with disease free and overall survival [DFS: Hazard Ratio (HR) = 2.61; 95% CI 1.32-5.17; P = 0.006; for OS: HR = 2.09; 95% CI 1.54-2.84; P < 0.001, respectively]. In multivariate Cox regression serum VEGF retained its prognostic value for DFS (HR = 2.10, P = 0.03) and OS (HR = 1.92, P = 0.04). Conclusions Serum VEGF levels correlate with more advanced and more aggressive disease in cervical cancer and may be a useful prognostic factor in patients with cervical cancer. © 2008 Springer-Verlag.

Cite

CITATION STYLE

APA

Zusterzeel, P. L. M., Span, P. N., Dijksterhuis, M. G. K., Thomas, C. M. G., Sweep, F. C. G. J., & Massuger, L. F. A. G. (2009). Serum vascular endothelial growth factor: A prognostic factor in cervical cancer. Journal of Cancer Research and Clinical Oncology, 135(2), 283–290. https://doi.org/10.1007/s00432-008-0442-y

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free